Medlab is doing some great work in the field of understanding the microbiome, and more importantly, targeting ways to address diseases through it. The company’s work with medical cannabis is also ground-breaking. Medlab Clinical has certainly given shareholders an interesting journey so far – expect that to continue as it rolls out fresh bacteria-based medicines, and develops its nanotech delivery platform.
Read MoreIt’s a fairly obvious truth in the funds management world, but not everybody wants to try it: to beat the index, you have to have a portfolio that differs from the index.
Read MoreWith Australia experiencing, in common with many other developed countries, an ageing population, the aged care business is clearly one with good prospects. Aged care and retirement living is now a hot mini-sector on the stock market, as investors hone in on the companies that offer services to the estimated four million-plus Australians born between 1946 and 1961.
Read MoreOne of the most difficult things with share investing is striking the right balance between timing and direction. As the saying goes – it’s time in the market not timing the market. Fortunately newly issued Bonus Certificates aim to provide investors with a positive return even in the event the pendulum doesn’t swing their way regarding direction and timing.
Read MoreAustralia is highly regarded in the world of biotechnology and medical devices, and it is companies like Ellex Medical Lasers Limited (ELX) that have generated this reputation. Established in 1985 and listed on the Australian Securities Exchange (ASX) in 2001, the Adelaide-based Ellex is a world leader in medical technologies for the diagnosis and treatment of eye disease: it produces lasers and diagnostic equipment for the treatment of various stages of blindness and eye disease.
Read MoreFakes are big business. The International Chamber of Commerce (ICC) estimates that the global cost of counterfeit trade reached US$1.7 trillion last year. According to the World Customs Organisation (WCO), 7 per cent of total world trade is counterfeit, worth an estimated US$600 billion a year. Research firm Havoscope.com estimates that the value of the global counterfeit industry by product is currently US$641 billion, with pharmaceuticals accounting for almost one-third of the value.
Read MoreThe Australian Securities Exchange (ASX) has ambitions to be a regional stock exchange, and actively seeks foreign companies to list, but even it would have been surprised at an approach it received last year.
Read MoreAs Australia gets its head around the opportunity of supplying the Chinese market with “soft” commodities and edible products – instead of just shipping off rocks – there will be the inevitable mis-steps. You only have to think of the rhetoric of late last century, when Australia was mooted as the “food bowl of Asia,” as if the nation could grow massive amounts of bulk food to supply burgeoning Asian populations.
Read More“Caring for the environment” is something virtually everyone says that they do: it’s not something you can be against. But few companies live the mantra like environmental technology and consulting company Pacific Environment Limited (PEH) – its business gives companies and governmental organisations the actual tools they need to care for the environment, and minimise their impact on it.
Read MoreThe wearable device revolution is upon us, and Australian medical device company DorsaVi Limited (DVL) is in the thick of it. But not in the consumer wearables sector: you won’t see DorsaVi competing with FitBit, Garmin, Jawbone and Apple with the latest must-have wearable heart-rate and fitness tracker.
Read MoreShane Oliver, head of investment strategy and chief economist at AMP Capital, is not bullish on markets, but nor is he overly bearish. Oliver, who leads a team that invests $50 billion in assets, says the dynamic asset allocation process that AMP uses is “telling us to reallocate to equities.”
Read MoreAfter the NewSat debacle, Australian investors could be forgiven for being leery of the word “satellite.” But the stock market is a Darwinian environment, and the lurid collapse of NewSat Limited last year was a great opportunity for global satellite communications service provider SpeedCast International (SDA) to pick over the carcase of its fallen rival.
Read MoreIt’s not very often that a fund manager tells investors to sell out of his funds, but Geoff Wilson is doing exactly that.
Read MoreThere is an old stock market saying that the market “climbs a wall of worry” – well, if that is true, 2016 should be a great year.
Read MoreWhat makes a good float? Unfortunately, that is one of those things that is only apparent in hindsight. Companies don’t necessarily have to hit the ASX screens with a bang, but they do have to have some attributes, or potential, or “story” to impress the market. Here are snapshots of the five best floats of the year.
Read More
